Purpose: To investigate sensory nerve conduction of the caudal nerve in normal and diabetic rats.
Methods: Diabetes was induced in twenty 8-weeks old Wistar male rats. Twenty normal rats served as controls. Caudal nerve conduction studies were made before diabetes induction and the end of each week for six consecutive weeks. The caudal nerve was stimulated distally and nerve potentials were recorded proximally on the animal's tail using common "alligator" clips as surface electrodes.
Results: After induction, nerve conduction velocities (NCV) increased slower in the diabetic than in the control group. Sensory nerve action potentials (SNAP) conduction velocities increased slower in the diabetic than in the control group (slope of regression line: 0.5 vs 1.3m/s per week; NCV in the 15(th) week = 39±3m/s vs 44±4m/s). Tukey's tests showed differences between groups at the 11th, 13(th) and 15(th) weeks old. From the 10(th) week on, SNAP amplitudes increased faster in the diabetic than in the control group (slopes of the regression line: 10 vs 8µV per week; SNAP amplitudes in the 15(th) week: 107±23µV vs 85±13µV). Differences at the 12(th), 13(th) and 15(th) weeks were significant.
Conclusion: In diabetic rats nerve conduction velocities were slower whereas amplitudes were larger than in normal rats.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s0102-86502011000200008 | DOI Listing |
Biomed Pharmacother
January 2025
Laboratory for Functional Imaging & Research on Stem Cells, BIOMED, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium. Electronic address:
Charcot-Marie-Tooth disease type 1A (CMT1A) is an inherited peripheral neuropathy caused by a duplication of the peripheral myelin protein 22 (PMP22) gene. It is primarily marked by Schwann cell dedifferentiation and demyelination, leading to motor and sensory deficits. Cyclic adenosine monophosphate (cAMP) is crucial for Schwann cell differentiation and maturation.
View Article and Find Full Text PDFWorld J Clin Cases
January 2025
Department of Medical Imaging, Chongqing University Central Hospital, Chongqing 400014, China.
Foot reflexology is a non-invasive and safe complementary therapy that works by massaging the reflex zones of the feet and exerts systemic or whole-body regulation through meridian nerve conduction. This therapy is commonly used in the treatment of various conditions such as autism and Parkinson's disease. However, there is limited reporting on the use of foot reflexology therapy for infants with sensorineural hearing loss (SNHL).
View Article and Find Full Text PDFBrain
January 2025
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Nerve conduction F-wave studies contain critical information about subclinical motor dysfunction which may be used to diagnose patients with amyotrophic lateral sclerosis (ALS). However, F-wave responses are highly variable in morphology, making waveform interpretation challenging. Artificial Intelligence techniques can extract time-frequency features to provide new insights into ALS diagnosis and prognosis.
View Article and Find Full Text PDFJ Arrhythm
February 2025
Department of Cardiology Saitama Medical University, International Medical Center Hidaka Japan.
Background: A novel contact force (CF) sensing catheter with a mesh-shaped irrigation tip (TactiFlexTM SE, Abbott), is expected to provide safe and effective radiofrequency ablation. Our previous study revealed that the TactiFlex catheter needs a higher power for pulmonary vein isolation (PVI) due to the long tip length. This study aimed to examine the feasibility and safety of a 50 W ablation with the TactiFlex for PVI of atrial fibrillation (AF).
View Article and Find Full Text PDFACS Pharmacol Transl Sci
January 2025
Department of Pharmacology and Toxicology, University of Kansas, Lawrence, Kansas 66045, United States.
Mutations in connexin 32 (Cx32) are a common cause of Charcot-Marie-Tooth 1X (CMT1X) disease, an inherited peripheral neuropathy characterized by progressive neuromuscular weakness and demyelination. There are no approved pharmacologic therapies for CMT1X, and identifying new treatments that slow the onset and severity of neuromuscular decline may aid disease management. Cemdomespib is an orally bioavailable small molecule that improved demyelination and neuromuscular junction (NMJ) morphology in mice lacking Cx32 expression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!